FDA approves Cadence's IV acetaminophen

FDA approved an NDA from Cadence Pharmaceuticals Inc. (NASDAQ:CADX) for Ofirmev IV acetaminophen to treat pain and fever. As part of the approval, Cadence will conduct a postmarketing efficacy study of Ofirmev in infants and neonates. Cadence plans on launching Ofirmev (formerly Acetavance) in the U.S. in 1Q11. ...